Results 11 to 20 of about 311,440 (293)

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

Haematologica, 2011
Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach   +5 more
doaj   +1 more source

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

Haematologica, 2012
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, Gautam Borthakur   +10 more
doaj   +1 more source

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

Haematologica, 2008
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini, Cristina Mecucci, Giuseppe Saglio, Francesco Lo Coco, Daniela Diverio, Patrick Brown, Fabrizio Pane, Marco Mancini, Maria Paola Martelli, Stefano Pileri, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger   +12 more
doaj   +1 more source

Clinical and molecular characterization of early T-cell precursor leukemia : a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations [PDF]

, 2012
A subgroup of pediatric acute T-lymphoblastic leukemia (T-ALL) was characterized by a gene expression profile comparable to that of early T-cell precursors (ETPs) with a highly unfavorable outcome.
Neumann, Martin, Heesch, Sandra, Gökbuget, Nicola, Schwartz, Stefan, Schlee, Cornelia, Benlasfer, Ouidad, Farhadi-Sartangi, Nasrin, Thibaut, Julia, Burmeister, Thomas, Hoelzer, Dieter, Hofmann, Wolf-Karsten, Thiel, Eckhard, Baldus, Claudia   +12 more
core   +1 more source

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

Haematologica, 2010
Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Jingsong Zhao, Eric D. Hsi, Arie Abo, Wouter Korver   +6 more
doaj   +1 more source

Targeting self-renewal pathways in myeloid malignancies [PDF]

, 2013
A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core   +2 more sources

Role of vitamin A/retinoic acid in regulation of embryonic and adult hematopoiesis [PDF]

, 2017
Vitamin A is an essential micronutrient throughout life. Its physiologically active metabolite retinoic acid (RA), acting through nuclear retinoic acid receptors (RARs), is a potent regulator of patterning during embryonic development, as well as being ...
Adamo, Ana Cañete, Arguello, Cardoso, Dary, De Luca, Elena Cano, Gebremedhin, Gerster, Grande, Guo, Haussler, Kuwata, Lo-Coco, McLaren, Nervi, North, Ottersbach, O’Donnell, Ramón Muñoz-Chápuli, Rita Carmona, Ross, Testa, West   +23 more
core   +4 more sources

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

Haematologica, 2012
The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried, Claudia Bodner, Monika M. Pichler, Karin Lind, Christine Beham-Schmid, Franz Quehenberger, Wolfgang R. Sperr, Werner Linkesch, Heinz Sill, Albert Wölfler   +9 more
doaj   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources